Coronaridine congeners potentiate GABA


Journal

Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617

Informations de publication

Date de publication:
13 07 2020
Historique:
received: 30 11 2019
revised: 13 03 2020
accepted: 15 03 2020
pubmed: 21 3 2020
medline: 5 6 2021
entrez: 21 3 2020
Statut: ppublish

Résumé

To determine whether (+)-catharanthine induces sedative- or anxiolytic/anxiogenic-like activity in male mice, proper animal paradigms were used. The results showed that (+)-catharanthine induces sedative-like activity in the 63-72 mg/Kg dose range in a flumazenil-insensitive manner, but neither this effect nor anxiolytic/anxiogenic-like activity was observed at lower doses. To determine the underlying molecular mechanism of the sedative-like activity, electrophysiological and radioligand binding experiments were performed with (+)-catharanthine and (±)-18-methoxycoronaridine [(±)-18-MC] on GABA

Identifiants

pubmed: 32194202
pii: S0278-5846(19)31019-X
doi: 10.1016/j.pnpbp.2020.109930
pii:
doi:

Substances chimiques

GABA-A Receptor Agonists 0
Hypnotics and Sedatives 0
Receptors, GABA-A 0
Benzodiazepines 12794-10-4
Ibogaine 3S814I130U
coronardine 467-77-6
noribogaine 87T5QTN9SK
18-methoxycoronaridine KX8NQX91Z8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109930

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interest.

Auteurs

Hugo R Arias (HR)

Department of Pharmacology and Physiology, Oklahoma State University College of Osteopathic Medicine, Tahlequah, OK, USA. Electronic address: hugo.arias@okstate.edu.

Jean Luc Do Rego (JL)

Behavioral Analysis Platform SCAC, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France.

Jean Claude Do Rego (JC)

Behavioral Analysis Platform SCAC, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France.

Zhenglan Chen (Z)

Department of Pharmacology and Neuroscience, Institute for Health Aging, University of North Texas Health Science Center at Fort Worth, TX, USA.

Youssef Anouar (Y)

Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM U1239, Institute for Research and Innovation in Biomedicine of Normandy (IRIB) Rouen, France.

Petra Scholze (P)

Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Vienna, Austria.

Eric B Gonzales (EB)

Department of Pharmacology and Neuroscience, Institute for Health Aging, University of North Texas Health Science Center at Fort Worth, TX, USA.

Renqi Huang (R)

Department of Pharmacology and Neuroscience, Institute for Health Aging, University of North Texas Health Science Center at Fort Worth, TX, USA.

Abdeslam Chagraoui (A)

Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM U1239, Institute for Research and Innovation in Biomedicine of Normandy (IRIB) Rouen, France; Department of Medical Biochemistry, Rouen University Hospital, CHU de Rouen, France. Electronic address: abdeslam.chagraoui@univ-rouen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH